JP2019523260A - キラルペプチド - Google Patents

キラルペプチド Download PDF

Info

Publication number
JP2019523260A
JP2019523260A JP2019503646A JP2019503646A JP2019523260A JP 2019523260 A JP2019523260 A JP 2019523260A JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019503646 A JP2019503646 A JP 2019503646A JP 2019523260 A JP2019523260 A JP 2019523260A
Authority
JP
Japan
Prior art keywords
amino acid
peptide agent
tetramer peptide
tetramer
orn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019503646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523260A5 (enExample
Inventor
アンドリュー ディー． レビン，
アンドリュー ディー． レビン，
Original Assignee
カーノット， エルエルシー
カーノット， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーノット， エルエルシー, カーノット， エルエルシー filed Critical カーノット， エルエルシー
Publication of JP2019523260A publication Critical patent/JP2019523260A/ja
Publication of JP2019523260A5 publication Critical patent/JP2019523260A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
JP2019503646A 2016-04-11 2017-04-10 キラルペプチド Ceased JP2019523260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321168P 2016-04-11 2016-04-11
US62/321,168 2016-04-11
PCT/US2017/026869 WO2017180535A1 (en) 2016-04-11 2017-04-10 Chiral peptides

Publications (2)

Publication Number Publication Date
JP2019523260A true JP2019523260A (ja) 2019-08-22
JP2019523260A5 JP2019523260A5 (enExample) 2020-03-12

Family

ID=60042852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503646A Ceased JP2019523260A (ja) 2016-04-11 2017-04-10 キラルペプチド

Country Status (7)

Country Link
US (2) US10870678B2 (enExample)
EP (1) EP3442990A4 (enExample)
JP (1) JP2019523260A (enExample)
CN (1) CN109563131A (enExample)
AU (2) AU2017249218B2 (enExample)
CA (1) CA3020393A1 (enExample)
WO (1) WO2017180535A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7606966B2 (ja) 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ
KR20210093957A (ko) 2018-12-18 2021-07-28 스텔스 바이오테라퓨틱스 코포레이션 미토콘드리아-표적화 펩타이드
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
US20210255196A1 (en) * 2020-01-17 2021-08-19 Waters Technologies Corporation Low binding surfaces for peptide mapping
KR20220151628A (ko) * 2020-03-06 2022-11-15 알레그로 파마슈티칼스, 엘엘씨 미토콘드리아 기능의 손상을 개선하거나 감소시키기 위한 치료
AU2020454871A1 (en) 2020-06-25 2023-01-19 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521355A (ja) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
JP2013501802A (ja) * 2009-08-12 2013-01-17 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
EP2197451A1 (en) 2007-06-07 2010-06-23 Institute For Hepatitis And Virus Research 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses
JP5697450B2 (ja) * 2007-10-02 2015-04-08 マリーナ バイオテック，インコーポレイテッド 核酸の送達のためのリポペプチド
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
JP5238297B2 (ja) 2008-03-04 2013-07-17 シャープ株式会社 認証方法および入力装置
EP3150215A1 (en) 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN102711785A (zh) 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
EP3100739A1 (en) 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN104725472A (zh) 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2011106717A1 (en) 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN105879008A (zh) 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3488941A1 (en) 2011-03-24 2019-05-29 Cornell University Aromatic-cationic peptides and uses of same
CN103764159A (zh) 2011-06-14 2014-04-30 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3078384A1 (en) 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
EP3170506B1 (en) 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2013155334A1 (en) 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6272853B2 (ja) * 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US20140034183A1 (en) 2012-07-31 2014-02-06 Viz Enterprises, Llc Cap assembly for dispensing a dispensable component and method of making and using the same
MX2015005102A (es) 2012-10-22 2016-02-09 Stealth Peptides Int Inc Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
US20160193278A1 (en) 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160175379A1 (en) 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
EP3049096B1 (en) 2013-09-27 2018-12-12 Cornell University Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
JP2016539931A (ja) 2013-10-23 2016-12-22 株式会社カネカ テトラペプチド化合物及びその製造方法
EP3077049B1 (en) 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
CN112457368A (zh) 2013-12-27 2021-03-09 康德生物医疗技术公司 药学相关的芳香族阳离子肽
EP2913287B1 (en) 2014-02-26 2018-01-03 Otis Elevator Company Governor for controlling the speed of a hoisted object relative to a guide member
CA2942143A1 (en) 2014-03-03 2015-09-11 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides and methods of generating the same
WO2016004441A1 (en) 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521355A (ja) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
JP2013501802A (ja) * 2009-08-12 2013-01-17 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHINOYAMA, M., ET AL.: ""Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), multifunctional opioid peptide,", CHEM. BIOL. DRUG DES., vol. 80, no. 5, JPN6020050087, 2003, pages 771 - 774, ISSN: 0004604958 *

Also Published As

Publication number Publication date
EP3442990A4 (en) 2019-12-18
US10870678B2 (en) 2020-12-22
AU2017249218B2 (en) 2020-08-27
US20190153032A1 (en) 2019-05-23
CA3020393A1 (en) 2017-10-19
CN109563131A (zh) 2019-04-02
US20200407395A1 (en) 2020-12-31
WO2017180535A1 (en) 2017-10-19
EP3442990A1 (en) 2019-02-20
AU2020260489A1 (en) 2020-11-26
AU2017249218A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US10870678B2 (en) Chiral peptides
JP5841672B2 (ja) Ｎ−ベンジルアニリン誘導体及びその使用
TW201117826A (en) Fatty acid niacin conjugates and their uses
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
KR102645633B1 (ko) 신경학적 장애를 치료하는 방법
CN109925312A (zh) 用于治疗眼病的组合物、制剂和方法
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
JP2021169519A (ja) 新規な細胞透過性サクシネート化合物
JP6666899B2 (ja) Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US12097179B2 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
KR20120089806A (ko) 구안파신의 전구 약물
TW201240662A (en) Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US7585846B2 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
JP2025138792A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
KR20250089568A (ko) 진통제 폴리펩티드
RS66246B1 (sr) Derivati para-hidrohinona kao vegf, tnf i/ili il inhibitori za lečenje neuroinflamtornih bolesti
WO2019006692A1 (zh) 用于治疗、改善或预防神经系统相关病症的化合物及其用途
JP2012530764A (ja) メキシレチンのアミノ酸およびペプチドプロドラッグ並びにその使用
CN118178369A (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
US20060160748A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
JP6987104B2 (ja) パ−キンソン病治療用の新規高透過薬物及びその組成物
JP6596483B2 (ja) パ−キンソン病治療用の新規高透過薬物及びその組成物
JP2004168697A (ja) 網膜疾患治療剤
TW202425961A (zh) 一種κ阿片受體激動劑藥物組合物及其製備方法和用途
WO2020214518A1 (en) Methods of treating renal conditions using peptides that improve mitochondrial function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211001

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220217